ASCO 2023 | PSMAddition: 177Lu-PSMA-617 plus standard of care vs SoC alone in patients with mHSPC

Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, discusses the PSMAddition trial (NCT04720157) which aims to evaluate the effectiveness and safety of Lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617) in combination with standard of care (SoC) compared to SoC alone in adults with metastatic hormone-sensitive prostate cancer (mHSPC). The study will enroll approximately 1,126 patients who are treatment-naive or minimally treated for hormonal therapy, have PSMA-positive disease, and meet other eligibility criteria. The primary endpoint is radiographic progression-free survival (rPFS), with overall survival (OS) as a key secondary endpoint. The trial also includes various secondary endpoints, such as PSA decline, time to development of metastatic castration-resistant prostate cancer, safety, and quality of life. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.